Treatment Effect Sizes of Once-Daily Valbenazine for Tardive Dyskinesia and for Chorea Associated with Huntington’s Disease: A Post-Hoc Analysis of Phase 3 Clinical Trial Data
Objective: To assess the treatment effect size of once-daily valbenazine for tardive dyskinesia (TD) and for chorea associated with Huntington’s disease (HD) using data from…Deciphering the Huntington’s Disease Research Landscape: A Comprehensive Bibliometric and Trend Analysis
Objective: To map the Huntington's Disease research landscape, identifying key trends, gaps, and the most impactful studies to guide future research directions and therapeutic strategies.…Mapping the Efficacy Landscape: A Network Meta-Analysis of Pharmacological Interventions in Huntington’s Disease
Objective: To evaluate and compare the efficacy of pharmacological interventions for Huntington's Disease through a network meta-analysis, identifying the most effective treatments. Background: Huntington’s Disease…Huntington’s Disease Pathogenesis, Molecular Factors, and Potential for Combinatorial Therapies: A Focus on BDNF and NMDA Receptor Therapies
Objective: This paper outlines current therapeutic options for HD, and ultimately suggests taking a combinatorial therapeutic approach to slow HD progression by simultaneously treating multiple…Shifting Paradigms In Huntington’s Disease Research: A Five-Year Scopus-Based Bibliometric Exploration
Objective: This study aimed to investigate the shifting trends (2019-2024) in research on Huntington's disease (HD)based on bibliometric lens. Background: Huntington's disease is a movement…Hazard ratios of suicidality in a large Huntington disease population compared with controls: marginal structural modeling of Enroll-HD registry data
Objective: The aim of this study was to describe the risk of suicidality among individuals with versus those without Huntington disease (HD) from Enroll-HD. Background:…Effects of a small molecule angiotensin IV analog on Huntington’s disease animal model
Objective: The present study was designed to test if N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide (AngIV-6a), an angiotensin IV analog, could attenuate 3-nitropropionic acid-induced Huntington’s disease-like symptoms in…Telemedicine and in-person encounters in a Huntington’s disease cohort: virtually the same
Objective: The aim of this study was to assess the impact of virtual care provision modalities (VPM) on patient satisfaction (PS) metrics for the specialized…Emerging treatments targeting DNA and RNA in Huntington’s disease: a review of future perspectives and current challenges
Objective: To review the progress made towards the development of a huntingtin (HTT) lowering strategy based on RNA and DNA and also to assess the…A case of trichotillomania as the preceding symptom of Huntington’ s diseaseand the effect of risperidone
Objective: Huntington's disease (HD) is a rare neurodegenerative disorder inherited by an autosomal dominant fashion which is most commonly characterised by choreic movement disorders. However,…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 9
- Next Page »